Who backs AgomAb?
17 investors| Investor | Type |
|---|---|
| Fidelity Management & Research Company | Asset manager |
| Canaan Partners | Venture capital |
| The Invus Group | PE / buyout |
| Cormorant Asset Management | Venture capital |
| EQT Life Sciences | Venture capital |
| Omnes Capital | PE / buyout |
| Andera Partners | PE / buyout |
| Boehringer Ingelheim Venture Fund | Other |
| Redmile Group | PE / buyout |
| Asabys Partners | Venture capital |
| + 7 more investors · a free account shows the complete list | |
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns
Membership and data by Private Market View
AgomAb investors
17 investors are on record for AgomAb, including Fidelity Management & Research Company, Canaan Partners, The Invus Group and Cormorant Asset Management. By type, the record holds 4 venture capital firms, 4 private equity firms and 1 hedge fund. The Series C in Oct 2023 drew 3 investors.
Free account
More of AgomAb with a free account
- ·The complete investor list: 17 names
- ·Watch AgomAb: the Monday email on marks, rounds and moves
For fundraisers
Work this list, don’t just read it
These 17 firms already write checks for companies like AgomAb in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.
Membership and data by Private Market View